Search

Author/Creator Shuster, Dale E.

1. Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy. Issue 5 (21st March 2023)

Authors:
Zahir, Hamim; Yin, Ophelia; Hsu, Ching; Wagner, Andrew J.; Jiang, Jason; Wang, Xiaoning; Greenberg, Jon; Shuster, Dale E.; Kakkar, Tarundeep; LaCreta, Frank
Journal:
Clinical pharmacology in drug development
Issue:
Volume 12:Issue 5(2023)
Page Start:
475
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors. Issue 6 (16th November 2020)

Authors:
Gelderblom, Hans; Wagner, Andrew J.; Tap, William D.; Palmerini, Emanuela; Wainberg, Zev A.; Desai, Jayesh; Healey, John H.; van de Sande, Michiel A. J.; Bernthal, Nicholas M.; Staals, Eric L.; Peterfy, Charles G.; Frezza, Anna Maria; Hsu, Henry H.; Wang, Qiang; Shuster, Dale E.; Stacchiotti, Silvia
Journal:
Cancer
Issue:
Volume 127:Issue 6(2021)
Page Start:
884
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. (24th December 2020)

Authors:
Lewis, James H.; Gelderblom, Hans; van de Sande, Michiel; Stacchiotti, Silvia; Healey, John H.; Tap, William D.; Wagner, Andrew J.; Pousa, Antonio Lopez; Druta, Mihaela; Lin, Chia‐Chi; Baba, Hideo A.; Choi, Youngsook; Wang, Qiang; Shuster, Dale E.; Bauer, Sebastian
Journal:
Oncologist
Issue:
Volume 26:Number 5(2021)
Page Start:
e863
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗